Pediatric post-transplant diabetes: Data from a large cohort of pediatric heart-transplant recipients

American Journal of Transplantation

Volumn 3, Issue 8, 2003, Pages 994-998

  Hathout, Eba H ^a   Chinnock, Richard E ^a   Johnston, Joyce K ^a   Fitts, James A ^a   Razzouk, Anees J ^a   Mace, John W ^a   Bailey, Leonard L ^a  

^a LOMA LINDA UNIVERSITY CHILDREN S HOSPITAL   (United States)

Author keywords

Pediatrics; Post transplant diabetes; Tacrolimus

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; C PEPTIDE; CYCLOSPORIN; GLUCOCORTICOID; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INSULIN; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PANCREAS ISLET CELL ANTIBODY; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ARTICLE; CHILD; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; PEDIATRIC SURGERY; POSTOPERATIVE PERIOD;

ADOLESCENT; ANTILYMPHOCYTE SERUM; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYCLOSPORINE; DIABETES MELLITUS; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; RETROSPECTIVE STUDIES;

EID: 0043267632     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00186.x     Document Type: Article

References (20)

1. Nieuwenhuis MG, Kirkels JH. Predictability and other aspects of post-transplant diabetes mellitus in heart transplant recipients. J Heart Lung Transplant 2001; 20: 703-708.
2. First MR, Gerber DA, Hariharan S et al. Posttransplant diabetes mellitus in kidney allograft recipients, incidence, risk factors, and management. Transplantation 2002; 73: 379-386.
3. Greenspan LC, Gitelman SE, Leong MA et al. Increased incidence in post-transplant diabetes mellitus in children: a case-control analysis. Pediatr Nephrol 2002; 17: 1-5.
4. Al-Uzri A, Stablein DM, Cohn R et al. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 72: 1020-1024.
5. Paolillo JA, Boyle GJ, Law YM et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. Transplantation 2001; 71: 252-256.
6. Shapiro R, Scantlebury VP, Jordan ML et al. Tacrolimus in pediatric renal transplantation. Transplantation 1996; 62: 1752-1758.
7. Hathaway DK, Tolley EA, Blakely ML et al. Development of an index to predict posttransplant diabetes mellitus. Clin Transplant 1993; 7: 330-338.
8. Miles AM, Sumrani N, Horowitz R et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 1998; 65: 380-384.
9. Boudreaux JP, McHugh L, Canafax DM et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376-381.
10. Clark MJ, Jr, Sterrett JJ, Carson DS et al. Diabetes guidelines: a summary and comparison of the recommendations of the American Diabetes Association, Veterans Health Administration, and American Association of Clinical Endocrinologists. Clin Ther 2000; 22: 899-910 discussion 898.
11. Meier-Kriesche HU, Arndorfer JA, Kaplan B et al. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 2002; 73: 70-74.
12. Barlow SE, Dietz WH. Management of child and adolescent obesity: summary and recommendations based on reports from pediatricians, pediatric nurse practitioners, and registered dietitians. Pediatrics 2002; 110 (1 Part 2): 236-238.
13. Hjelmesaeth J, Hartmann A, Kofstad J et al. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant 2001; 16: 829-835.
14. Midtvedt K, Hartmann A, Hjelmesaeth J et al. Insulin resistance is a common denominator of post-transplant diabetes mellitus and impaired glucose tolerance in renal transplant recipients. Nephrol Dial Transplant 1998; 13: 427-431.
15. Lohmann T, List C, Lamesch P et al. Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunosuppressive therapy by FK506/tacrolimus. Exp Clin Endocrinol Diabetes 2000; 108: 347-352.
16. Wakugami T, Islam MR, Higa S et al. Effect of FK506 on the development of diabetes in BB rats in comparison with that of cyclosporin. Tohoku J Exp Med 1993; 169: 21-29.
17. Moxey-Mims MM, Kay C, Light JA et al. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506). Transplantation 1998; 65: 617-619.
18. Furth S, Neu A, Colombani P et al. Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients. Pediatr Nephrol 1996; 10: 64-66.
19. Toyonaga T, Kondo T, Miyamura N et al. Sudden onset of diabetes with ketoacidosis in a patient treated with FK506/ tacrolimus. Diabetes Res Clin Pract 2002; 56: 13-18.
20. Yoshioka K, Sato T, Okada N et al. Post-transplant diabetes with anti-glutamic acid decarboxylase antibody during tacrolimus therapy. Diabetes Res Clin Pract 1998; 42: 85-89.